COMMUNIQUÉS West-GlobeNewswire

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
23/04/2026
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data [...]
AVITA Medical to Announce First Quarter 2026 Financial Results
23/04/2026
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial [...]
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
23/04/2026
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab [...]
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
23/04/2026
Appointment strengthens Board’s clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a [...]
This Alcohol Awareness Month, Oxford Treatment Center Raises Red Flag, Citing Significant Rise in Patients Seeking Help for Alcohol Addiction
23/04/2026
ETTA, Miss., April 23, 2026 (GLOBE NEWSWIRE) -- With April designated as Alcohol Awareness Month, Oxford Treatment Center, a leading provider of addiction and co-occurring disorder treatment in Mississippi, is sounding [...]
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
23/04/2026
Announcement no. 04/2026 Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in [...]
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
23/04/2026
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit [...]
Hormify Launches Transparent, Research-Based Supplement for Hormonal Balance and Daily Wellness
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Hormify today announced the introduction of its transparent, research-based dietary supplement formulated to support hormonal balance, mood, and energy. Produced in FDA- [...]
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
23/04/2026
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices [...]
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026 [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2026
23/04/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses
23/04/2026
TUSCALOOSA, Ala., April 23, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral asset portfolio, establishing the Company [...]
Q1 2026 revenue
23/04/2026
Q1 2026 revenue Quarterly activity Revenue: €177.4m, up 2.6% at CER 1 and on a like-for-like basis 2 Increase driven by EMEA (+4.5%), with an improvement in the situation in France, and by Asia (+6.0%); a decline in the [...]
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
23/04/2026
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint [...]
FSR, in Partnership with ATS, Welcomes Dr. Matt Craig to Drive Strategic Research Initiatives
23/04/2026
CHICAGO, April 23, 2026 (GLOBE NEWSWIRE) -- Through the long-standing collaboration between Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS), FSR and ATS are pleased to announce that [...]
First-quarter 2026 revenue
23/04/2026
Press release Revenue as at 31 March 2026 stood at €1 , 336m , up +4.9% on an organic basis compared with the first quarter of 2025 All business segments and regions contributed to revenue growth, supported by [...]
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
23/04/2026
Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction [...]
Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting
23/04/2026
VIVO System to be featured in educational sessions at HRS Accepted manuscripts for LockeT and VIVO are now published and available online FORT MILL, S.C., April 23, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. ( [...]
Chiffre d'affaires du 1er trimestre 2026
23/04/2026
Communiqué de presse Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m , en progression de +4,9% en base organique par rapport au 1 er trimestre 2025 L’ensemble des activités et des régions contribue à la [...]

Pages